Guangzhou Baiyunshan Pharmaceutical Holdings (0874.HK) Earnings Analysis
Guangzhou Baiyunshan Pharmaceutical Holdings (0874.HK) next reports earnings on 2026-08-22. It has beaten estimates in 1/5 recent quarters (20%). Trailing P/E 12.03.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does 0874.HK next report earnings?
| Next earnings date | 2026-08-22 |
|---|---|
| Consensus EPS estimate | n/a |
| Revenue estimate | n/a |
0874.HK earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-04-27 | 1.25 HKD | n/a | n/a | n/a |
| 2026-03-20 | -0.2225 HKD | 0.4897 HKD | -145.4% | Miss |
| 2025-04-29 | 1.2 HKD | 0.59 HKD | +103.4% | Beat |
| 2025-03-13 | -0.2147 HKD | 0.31 HKD | -169.3% | Miss |
| 2024-10-25 | 0.38 HKD | 0.45 HKD | -15.6% | Miss |
| 2024-08-30 | 0.36 HKD | 0.51 HKD | -29.4% | Miss |
Beat rate: 1/5 (20%) over reported quarters with consensus data.
0874.HK valuation and analyst view
| Trailing P/E | 12.03 |
|---|---|
| Trailing EPS | 1.812 HKD |
| Price / book | 0.90 |
| Dividend yield | 3.88% |
| Market cap | 39.16B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is Guangzhou Baiyunshan Pharmaceutical Holdings (0874.HK)'s next earnings date?
Guangzhou Baiyunshan Pharmaceutical Holdings is next scheduled to report on 2026-08-22.
Did 0874.HK beat earnings last quarter?
Consensus estimate data was not available for 0874.HK's 2026-04-27 report.
What is 0874.HK's earnings track record?
Over the last 5 reported quarters with consensus data, 0874.HK beat estimates 1 times (20%).
What is 0874.HK's current P/E ratio and EPS?
0874.HK trades at a trailing P/E of 12.03 on trailing EPS of 1.811767528544567 HKD.
What do analysts rate 0874.HK?
0874.HK has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.